OLX 101A
Alternative Names: OLX 10010; OLX 101; OLX-101ALatest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator OliX Pharmaceuticals
- Developer Hugel; OliX Pharmaceuticals
- Class Antifibrotics; Eye disorder therapies; Skin disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypertrophic scars
- No development reported Dry age-related macular degeneration; Pulmonary fibrosis; Wet age-related macular degeneration
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Hypertrophic-scars(In volunteers) in United Kingdom (Intradermal, Injection)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Hypertrophic-scars(In volunteers) in United Kingdom (SC, Injection)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in South Korea